DE69810635T2 - Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust - Google Patents
Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlustInfo
- Publication number
- DE69810635T2 DE69810635T2 DE69810635T DE69810635T DE69810635T2 DE 69810635 T2 DE69810635 T2 DE 69810635T2 DE 69810635 T DE69810635 T DE 69810635T DE 69810635 T DE69810635 T DE 69810635T DE 69810635 T2 DE69810635 T2 DE 69810635T2
- Authority
- DE
- Germany
- Prior art keywords
- preventing
- hearing loss
- treating hearing
- neurturin protein
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5418497P | 1997-07-30 | 1997-07-30 | |
US09/106,486 US6043221A (en) | 1997-07-30 | 1998-06-29 | Method for preventing and treating hearing loss using a neuturin protein product |
PCT/US1998/014600 WO1999006064A1 (en) | 1997-07-30 | 1998-07-17 | Method for preventing and treating hearing loss using a neurturin protein product |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69810635D1 DE69810635D1 (de) | 2003-02-13 |
DE69810635T2 true DE69810635T2 (de) | 2003-05-28 |
Family
ID=26732740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69810635T Expired - Fee Related DE69810635T2 (de) | 1997-07-30 | 1998-07-17 | Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust |
Country Status (10)
Country | Link |
---|---|
US (2) | US6043221A (de) |
EP (1) | EP1005358B1 (de) |
JP (1) | JP2001525316A (de) |
AT (1) | ATE230607T1 (de) |
AU (1) | AU8658298A (de) |
CA (1) | CA2298414C (de) |
DE (1) | DE69810635T2 (de) |
DK (1) | DK1005358T3 (de) |
ES (1) | ES2190093T3 (de) |
WO (1) | WO1999006064A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
DE19807426A1 (de) | 1998-02-23 | 1999-10-14 | Otogene Biotechnologische Fors | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
US6423321B2 (en) | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
DE60045350D1 (de) | 1999-06-01 | 2011-01-20 | Baylor College Medicine | Zusammensetzungen und verfahren zur therapeutischen anwendung einer mit dem gen atonal assoziierten sequenz |
US7053200B1 (en) | 1999-06-01 | 2006-05-30 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation |
DE10025152A1 (de) * | 2000-05-23 | 2001-12-06 | Marlies Knipper | Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit |
US20050222070A1 (en) | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
WO2003099318A2 (en) | 2002-05-29 | 2003-12-04 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Pancreas-specific proteins |
US20100030130A1 (en) * | 2001-11-09 | 2010-02-04 | Cochlear Limited | Pharmaceutical intervention for modulation of neural plasticity |
US20050171579A1 (en) * | 2001-11-09 | 2005-08-04 | Claudia Tasche | Stimulating device |
AUPR879201A0 (en) * | 2001-11-09 | 2001-12-06 | Cochlear Limited | Subthreshold stimulation of a cochlea |
US20100030301A1 (en) * | 2001-11-09 | 2010-02-04 | Cochlear Limited | Electrical stimulation for modulation of neural plasticity |
WO2003063789A2 (en) * | 2002-01-30 | 2003-08-07 | House Ear Institute | L-carnitine for treatment of hearing loss |
WO2004003020A1 (ja) * | 2002-06-27 | 2004-01-08 | Nippon Medical School Foundation | 外リンパ瘻の検出方法 |
WO2004016167A1 (en) * | 2002-08-16 | 2004-02-26 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
CN1703248A (zh) | 2002-10-02 | 2005-11-30 | 安琪士摩奇株式会社 | 用于听觉损害的药物制剂 |
WO2004066975A1 (en) | 2002-12-18 | 2004-08-12 | Hough Ear Institute | Otologic nanotechnology |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
PL1694354T3 (pl) | 2003-11-27 | 2009-12-31 | Develogen Ag | Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny |
US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
JP2008502788A (ja) * | 2004-06-08 | 2008-01-31 | アルザ コーポレイション | 4成分縮合反応による高分子コンジュゲートの調製 |
JP5548336B2 (ja) | 2004-06-15 | 2014-07-16 | コクレア リミテッド | 誘発神経応答閾値の自動決定 |
WO2006099325A2 (en) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methods of treating ear infections |
US8309057B2 (en) * | 2005-06-10 | 2012-11-13 | The Invention Science Fund I, Llc | Methods for elevating neurotrophic agents |
WO2007030743A2 (en) | 2005-09-08 | 2007-03-15 | Massachusetts Eye & Ear Infirmary | Cochlear implants containing biological cells and uses thereof |
EP1872790A1 (de) | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | Neue Zusammensetzung zur Erhöhung der Bioverfügbarkeit von Neurturin |
CA2742839A1 (en) * | 2007-11-05 | 2009-05-14 | Develogen Aktiengesellschaft | Novel neurturin conjugates for pharmaceutical use |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
RU2499592C2 (ru) | 2008-04-21 | 2013-11-27 | Отономи, Инк. | Фармацевтическая композиция для лечения ушных заболеваний |
BR112012009801A8 (pt) * | 2009-10-30 | 2016-08-30 | Cns Therapeutics Inc | Polipeptídeo neurturina e variante de neurturina |
US20110195402A1 (en) * | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Systems and methods for detecting drug use |
CA2951905A1 (en) * | 2014-06-12 | 2015-12-17 | Orbis Biosciences, Inc. | Extended-release drug delivery compositions |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
WO2020045980A1 (en) * | 2018-08-28 | 2020-03-05 | Industry-Academic Cooperation Foundation, Yonsei University | Pharmaceutical composition for treating or preventing sensorineural hearing loss |
CN110124014A (zh) * | 2019-05-16 | 2019-08-16 | 杭州师范大学 | 重组人神经突起生长因子Neuritin蛋白的应用及一种用于治疗听神经病的药物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5106627A (en) * | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
EP0401384B1 (de) * | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemisch modifizierte granulocytenkolonie erregender faktor |
WO1991010470A1 (en) * | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
HU220795B1 (hu) * | 1991-09-20 | 2002-05-28 | Amgen Inc. | Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére |
AU7568094A (en) * | 1993-08-12 | 1995-03-14 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
FR2717824B1 (fr) * | 1994-03-25 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
US5658785A (en) * | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
WO1997019693A1 (en) * | 1995-11-29 | 1997-06-05 | Amgen Inc. | Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
-
1998
- 1998-06-29 US US09/106,486 patent/US6043221A/en not_active Expired - Lifetime
- 1998-07-17 CA CA002298414A patent/CA2298414C/en not_active Expired - Fee Related
- 1998-07-17 EP EP98937956A patent/EP1005358B1/de not_active Expired - Lifetime
- 1998-07-17 DK DK98937956T patent/DK1005358T3/da active
- 1998-07-17 WO PCT/US1998/014600 patent/WO1999006064A1/en active IP Right Grant
- 1998-07-17 AT AT98937956T patent/ATE230607T1/de not_active IP Right Cessation
- 1998-07-17 JP JP2000504876A patent/JP2001525316A/ja active Pending
- 1998-07-17 AU AU86582/98A patent/AU8658298A/en not_active Abandoned
- 1998-07-17 DE DE69810635T patent/DE69810635T2/de not_active Expired - Fee Related
- 1998-07-17 ES ES98937956T patent/ES2190093T3/es not_active Expired - Lifetime
-
1999
- 1999-08-19 US US09/377,446 patent/US6274554B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK1005358T3 (da) | 2003-02-24 |
JP2001525316A (ja) | 2001-12-11 |
DE69810635D1 (de) | 2003-02-13 |
ATE230607T1 (de) | 2003-01-15 |
WO1999006064A1 (en) | 1999-02-11 |
EP1005358A1 (de) | 2000-06-07 |
EP1005358B1 (de) | 2003-01-08 |
AU8658298A (en) | 1999-02-22 |
CA2298414C (en) | 2004-09-28 |
US6274554B1 (en) | 2001-08-14 |
CA2298414A1 (en) | 1999-02-11 |
ES2190093T3 (es) | 2003-07-16 |
US6043221A (en) | 2000-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69810635T2 (de) | Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust | |
ATE211392T1 (de) | Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen | |
DE3877529D1 (de) | Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung. | |
DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
DE69527052D1 (de) | Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten | |
ATE319712T1 (de) | Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung | |
DE60008143D1 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
ATE316529T1 (de) | Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns) | |
ATE215373T1 (de) | 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss | |
ATE222119T1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
DE69626816D1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
DE60039579D1 (de) | Humane adulte astrozyten, sowie deren herstellung und verwendung | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
DE60040860D1 (de) | Mechanisch verlängerte neuronale zellen und methoden zur herstellung und verwendung dieser zellen | |
DE60318081D1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
EP1304119A3 (de) | Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein | |
NZ323207A (en) | Hemoregulatory compounds | |
DE69907685D1 (de) | Verwendung von derivaten von tetrahydropyridinen oder (4-hydroxypiperidin)-butylazolen zur herstellung von präparaten zur schmerzbehandlung | |
AU4210900A (en) | Products and methods for treating ptp lar related diseases | |
ATE79759T1 (de) | Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |